Influenza, including the novel H1N1, in organ transplant patients

Current Opinion in Infectious Diseases

Volumn 23, Issue 4, 2010, Pages 365-373

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

influenza; oseltamivir; solid organ transplantation; vaccination; zanamivir

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ANTIVIRAL THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VIRUS; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; PANDEMIC; PROGNOSIS; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; POSTOPERATIVE COMPLICATIONS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 77954887194     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833bc1c3     Document Type: Review

References (111)

1. Hayden FG, Palese P. Influenza virus. In Richman DD, Whitley RJ, Hayden FG, editors. Clinical virology. 3rd ed. ASM Press; 2009. pp. 943-976.
2. Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459: 1122-1125.
3. Garten RJ, Davis CT, Russell CA, etal. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
4. Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1 N1 in solid organ transplant recipients. Am J Transplant 2010; 10:18-25.
5. Weinberg A, Zamora MR, Li S, etal. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol 2002; 25:171-175.
6. Vilchez RA, McCurry K, Dauber J, etal. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2:287-291.
7. Meylan PR, Aubert JD, Kaiser L Influenza transmission to recipient through lung transplantation. Transpl Infect Dis 2007; 9:55-57.
8. Liu M, Mallory GB, Schecter MG, et al. Long-term impact of respiratory viral infection after pediatric lung transplantation. Pediatr Transplant 2010 [Epub ahead of print].
9. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. J Am Med Assoc 2009; 302:1872-1879.
10. Khalifah AP, Hachem RR, ChakinalaMM, etal. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170:181-187.
11. Jain S, Kamimoto L, BramleyAM, etal. Hospitalized patients with 2009 H1N1 influenza in the United States, April: June 2009. N Engl J Med 2009; 361:1935-1944.
12. Ison MG, Sharma A, Shepard JA, et al. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008; 27:282-288.
13. Hopkins P, McNeil K, Kermeen F, etal. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008; 178:876-881.
14. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37:471-484.
15. Gottlieb J, Schulz TF, Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009; 87:1530-1537.
16. Garantziotis S, Howell DN, McAdams HP, etal. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001; 119:1277-1280.
17. Danziger-Isakov LA, Husain S, Mooney ML, Hannan MM. The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation. J Heart Lung Transplant 2009; 28:1341-1347.
18. Chakinala MM, Walter MJ. Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences. Semin Thorac Cardiovasc Surg 2004; 16:342-349.
19. Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis 2001; 3:138-148.
20. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21:559-566.
21. Apalsch AM, Green M, Ledesma-Medina J, et al. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis 1995; 20:394-399.
22. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715-2729.
23. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1-52.
24. Gabriel R, Selwyn S, Brown D, et al. Virus infections and acute renal transplant rejection. Nephron 1976; 16:282-286.
25. Keane WR, Helderman JH, Luby J, et al. Epidemic renal transplant rejection associated with influenza A victoria. Proc Clin Dial Transplant Forum 1978; 8:232-236.
26. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. J Am Med Assoc 2009; 302:1896-1902.
27. Webb SA, Pettila V, Seppelt I, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925-1934.
28. Kumar D, Liu C, Michaels MG, et al. A multicenter study of clinical outcomes of novel influenza A/H1N1 infection in solid organ transplant recipients. In American Transplant Congress. San Diego, California; 2010 [Abstract #5].
29. Kaiser L, Fritz RS, Straus SE, et al. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001; 64:262-268.
30. Fritz RS, Hayden FG, Calfee DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999; 180:586-593.
31. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101:643-649.
32. Kaiser L, Hayden FG. Hospitalizing influenza in adults. Curr Clin Top Infect Dis 1999; 19:112-134.
33. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110:1681-1688.
34. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243-3247.
35. Ison MG, Rosenberg ES. RNA respiratory viruses. In Hayden RT, Carrol KC, Tang YW, Wolk DM, editors. Diagnostic microbiology of the immunocompromised host. ASM Press; 2008. pp. 141-160.
36. Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus: United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:826-829.
37. Drexler JF, Helmer A, Kirberg H, et al. Poor clinical sensitivity of rapid antigen test for influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis 2009; 15:1662-1664.
38. Taylor J, McPhie K, Druce J, et al. Evaluation of twenty rapid antigen tests for the detection of human influenza A H5N1, H3N2, H1N1,and B viruses. J Med Virol 2009; 81:1918-1922.
39. Kuypers J, Campbell AP, Cent A, et al. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis 2009; 11:298-303.
40. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493-504.
41. Rambal V, Mueller K, Nickel P, etal. Evaluation of safety and efficacy of H1N1 swine-origin influenza A vaccination in renal transplant patients. In American Transplant Congress. San Diego, California; 2010 [Abstract LB16].
42. Birdwell KA, Ikizler MR, Sannella EC, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009; 54:112-121.
43. Cavdar C, Sayan M, Sifil A, et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003; 37:71-76.
44. Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. Liver Transpl 2000; 6:531-542.
45. Kobashigawa JA, Warner-Stevenson L, Johnson BL, et al. Influenza vaccine does not cause rejection after cardiac transplantation. Transplant Proc 1993; 25:2738-2739.
46. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336-1343.
47. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-449.
48. Peters PH Jr, Gravenstein S, Norwood P, etal. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025-1031.
49. Dutkowski R, Thakrar B, Froehlich E, et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003; 26:787-801.
50. Aoki FY, Lam H, Jeffery J, Sitar DS. Oseltamivir does not interact pharma-cokinetically with cyclosporine, mycophenolate mofetil, or tacrolimus in renal transplant patients. In 43rd IDSA Annual Meeting. San Francisco; 2005 [Abstract 522].
51. Hill G, Cihlar T, Oo C, et al. The antiinfluenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002; 30:13-19.
52. Oo C, Barrett J, Dorr A, et al. Lack of pharmacokinetic interaction between the oral antiinfluenza prodrug oseltamivir and aspirin. Antimicrob Agents Chemother 2002; 46:1993-1995.
53. Snell P, OoC, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral antiinfluenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol 2002; 54:372-377. (Pubitemid 35334949)
54. Chik KW, Li CK, Chan PK, et al. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Med J 2004; 10:103-106.
55. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007; 45:187-193.
56. Ison MG, Szakaly P, Shapira MY, et al. Oseltamivir prophylaxis significantly reduces the incidence of seasonal influenza infection in immunocompro mised patients. XI International Symposium on Respiratory Viral Infections. Bangkok, Thailand; 2009.
57. Calfee DP, Peng AW, Hussey EK, et al. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther 1999; 4:143-149.
58. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343:1282-1289.
59. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582-1588.
60. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis: North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969-972.
61. Griffiths PD. Transmission of swine influenza through organ transplantation. Rev Med Virol 2010; 20:65-67.
62. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005; 352:686-691.
63. Johny AA, Clark A, Price N, et al. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:113-115.
64. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-1850.
65. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. J Am Med Assoc 2000; 283:1016-1024.
66. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-133.
67. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. J Am Med Assoc 2006; 295:891-894.
68. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents: United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 2006; 55: 44-46.
69. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-1373.
70. CDC Issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) Viruses, 2008-09 Influenza Season. CDC Health Advisory 2008.
71. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010; 115:1331-1342.
72. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007; 44:964-967.
73. Machado CM, Boas LS, Mendes AV, et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34:111-114.
74. Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompro mised host. J Infect Dis 2010 [Epub ahead of print].
75. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:2204-2207.
76. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11:100-105.
77. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
78. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31:695-700.
79. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13:437-440.
80. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine-and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-1424.
81. Hall CB, Dolin R, GalaCL, etal. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80:275-282.
82. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-1702.
83. Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35:1741-1747.
84. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-765.
85. Astrahan P, Kass I, Cooper MA, Arkin IT. A novel method of resistance for influenza against a channel-blocking antiviral drug. Proteins 2004; 55:251-257.
86. HayAJ,Zambon MC, Wolstenholme AJ, etal. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986; 18 (Suppl B):19-29.
87. Hurt AC, Ho HT, Barr I. Resistance to antiinfluenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther 2006; 4:795-805.
88. Sweet C, Hayden FG, Jakeman KJ, et al. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 1991; 164:969-972.
89. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-764.
90. The Writing Committee of the World Health Organization Consultation on Human Influenza AH. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-1385.
91. McKimm-Breschkin J, Trivedi T, Hampson A, etal. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-2272.
92. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103:199-203.
93. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12:603-616.
94. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13.
95. Ison MG. Antiinfluenza therapy: the emerging challenge of resistance. Therapy 2009; 6:883-891.
96. Shiraishi K, Mitamura K, Sakai-Tagawa Y, et al. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188:57-61.
97. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 (Suppl 1):i5-i21.
98. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 2006; 194 (Suppl 2):S133-S138.
99. Stephenson I, Democrats J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009; 15:389-396.
100. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348:867-868.
101. Hayden FG. Antiviral resistance in influenza viruses: implications for management and pandemic response. N Engl J Med 2006; 354:785-788.
102. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. J Am Med Assoc 2009; 301:1034-1041.
103. Gooskens J, Jonges M, Claas EC, et al. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. J Am Med Assoc 2009; 301:1042-1046.
104. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec 2009; 85:37-40.
105. Oseltamivir-resistant novel influenza A (H1 N1) virus infection in two immuno-suppressed patients: Seattle, Washington 2009. MMWR Morb Mortal Wkly Rep 2009;58:893-896.
106. Chan PA, Connell NT, Gabonay AM, et al. Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin Microbiol Infect 2010 [Epub ahead of print].
107. Deyde VM, Sheu TG, Trujillo AA, et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010; 54:1102-1110.
108. Speers DJ, Williams SH, Pinder M, et al. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust 2010; 192:166-168.
109. Zaraket H, Saito R, Suzuki Y, et al. Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses. J Clin Microbiol 2010; 48:1085-1092.
110. Gulland A. First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales. Br Med J 2009; 339:b4975.
111. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190.